More Articles

Patient, health and trade groups say USMCA will keep drug prices high Policies & Legislation | Posted 30/11/2018

Patient, healthcare and trade groups have warned that the North American Free Trade Agreement (NAFTA), now known as the US-Mexico-Canada Free Trade Agreement (USMCA) will keep American drug prices...

Alvotech makes deal with Fuji Pharma for biosimilars in Japan Pharma News | Posted 30/11/2018

Iceland-based biopharmaceutical company Alvotech and Japan-based Fuji Pharma announced on 19 November 2018 that they had entered into an exclusive partnership for biosimilars in Japan.

Access! 2019 AAM Annual Meeting Conferences | Posted 30/11/2018

Access! 2019 AAM Annual Meeting 4–6 February 2019 Hyatt Regency New OrleansNew Orleans, LA, USA

International policies for interchangeability, switching and substitution of biosimilars Reports | Posted 23/11/2018

In its report into different international policies on the use of biosimilars, the Canadian Agency for Drugs and Technologies in Health (CADTH) investigated the issue of interchangeability, switchi...

Safety of originator and biosimilar epoetin alfa drugs Biosimilars/Research | Posted 23/11/2018

Researchers from Italy carried out a study to compare the safety profile of biosimilars with respect to the reference product in a nephrology setting. The results confirm the comparable safety prof...

Insulin glargine biosimilars launched in UK and South Korea Biosimilars/News | Posted 23/11/2018

November 2018 has seen the launch of insulin glargine biosimilars in both the UK and South Korea.

FDA strengthens and modernizes inspections for sterile injectable drugs Policies & Legislation | Posted 23/11/2018

On 9 November 2018, the US Food and Drug Administration (FDA) announced that it was taking new steps to modernize its inspections programme with a new way of assessing, recording and reporting the...

AbbVie makes more deals delaying adalimumab biosimilars in US Pharma News | Posted 23/11/2018

Last update: 14 December 2018US-based pharma giant AbbVie has signed yet more deals with biosimilars makers regarding biosimilar versions of its blockbuster arthritis drug Humira (adalimumab).